Tenax Therapeutics, Inc.
Tenax Therapeutics develops pharmaceutical products containing imatinib for pulmonary arterial hypertension treatment in the US. Products include TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) with completed phase II clinical trials. They also develop TNX-201 (imatinib) for chronic myeloid leukemia treatment. The company was previously known as Oxygen Biotherapeutics and changed its name to Tenax Therapeutics in 2014. Founded in 1967, the company is based in North Carolina.
Overview
Strengths
- Price to book ratio (0.02) is lower than the sector mean (24.44).
- EV/EBITDA (4.75) is lower than the sector mean (85.60).
- EV/EBIT (4.75) is lower than the sector mean.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (4.86) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | - |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | - |